Natalia Petros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalia Petros has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Philip McGuire
University of Oxford
7 shared publications - Sagnik Bhattacharyya
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
7 shared publications - Paolo Fusar-Poli
Early Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
6 shared publications - Ewa Klamerus
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
5 shared publications - Robin MacGregor Murray
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
5 shared publications Enrico Foglia
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, UK
4 shared publications
Latest Publications
- 27 November 2025
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 60, 58-70
Refining Aicardi Syndrome diagnostic Criteria: an expert-based consensus using a modified Delphi approach
- 27 November 2025
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 60, 58-70
Refining Aicardi Syndrome diagnostic Criteria: an expert-based consensus using a modified Delphi approach
- Open Access
- 1 June 2021
- Published by Elsevier in eClinicalMedicine
- Vol. 36, 100909
Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis
- 1 June 2021
- Published by Elsevier in eClinicalMedicine
- Vol. 36, 100909
Open AccessLongitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis
- 1 September 2020
- Published by Elsevier in Schizophrenia Research
- Vol. 223, 361-362
Towards standardising the assessment of good outcome in people at clinical high risk for psychosis: A collaborative approach
- 1 September 2020
- Published by Elsevier in Schizophrenia Research
- Vol. 223, 361-362
Towards standardising the assessment of good outcome in people at clinical high risk for psychosis: A collaborative approach
- Open Access
- 26 May 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (3) , 606-615
Examining service‐user perspectives for the development of a good outcome checklist for individuals at clinical high risk for psychosis
Aims: Around 15% of patients at clinical high risk for psychosis (CHR‐P) experience symptomatic remission and functional recovery at follow‐up, yet the definition of a good outcome (GO) in this population requires further development. Outcomes are typically designed and rated by clinicians rather than patients, to measure adverse as opposed to GOs. Here we investigate how CHR‐P subjects define a GO, with the aim of developing a checklist that could be used to measure GO in this clinical group.Methods: A set of GO‐focused questions were designed in collaboration with a service‐user. CHR‐P patients (n = 48) were asked to rate the importance of items that could indicate short‐term (1 year) and long‐term (5 years) GO. These items were then ranked using the relative importance index (RII).Results: Patients rated improvement in subjective wellbeing (RII = 0.829) and non‐specific presenting symptoms (RII = 0.817) amongst the factors most important for indicating GO in the short‐term, and improved resilience (RII = 0.879) and negative symptoms (RII = 0.858) as key items for indicating long‐term GO. Patients regarded building resilience (RII = 0.842) and having support from mental health services (RII = 0.833) as being protective for their mental health. These measures were included in a preliminary 12‐item GO checklist (GO‐12) for assessing GO in CHR‐P subjects.Conclusions: Patient‐defined measures of GO included items that are not incorporated into conventional measures of outcomes in CHR‐P subjects, such as subjective wellbeing and resilience. Integrating patient‐defined metrics of GO may improve the assessment of outcomes in the CHR‐P population.
- 26 May 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (3) , 606-615
Open AccessExamining service‐user perspectives for the development of a good outcome checklist for individuals at clinical high risk for psychosis
Aims: Around 15% of patients at clinical high risk for psychosis (CHR‐P) experience symptomatic remission and functional recovery at follow‐up, yet the definition of a good outcome (GO) in this population requires further development. Outcomes are typically designed and rated by clinicians rather than patients, to measure adverse as opposed to GOs. Here we investigate how CHR‐P subjects define a GO, with the aim of developing a checklist that could be used to measure GO in this clinical group.Methods: A set of GO‐focused questions were designed in collaboration with a service‐user. CHR‐P patients (n = 48) were asked to rate the importance of items that could indicate short‐term (1 year) and long‐term (5 years) GO. These items were then ranked using the relative importance index (RII).Results: Patients rated improvement in subjective wellbeing (RII = 0.829) and non‐specific presenting symptoms (RII = 0.817) amongst the factors most important for indicating GO in the short‐term, and improved resilience (RII = 0.879) and negative symptoms (RII = 0.858) as key items for indicating long‐term GO. Patients regarded building resilience (RII = 0.842) and having support from mental health services (RII = 0.833) as being protective for their mental health. These measures were included in a preliminary 12‐item GO checklist (GO‐12) for assessing GO in CHR‐P subjects.Conclusions: Patient‐defined measures of GO included items that are not incorporated into conventional measures of outcomes in CHR‐P subjects, such as subjective wellbeing and resilience. Integrating patient‐defined metrics of GO may improve the assessment of outcomes in the CHR‐P population.
- Open Access
- 22 August 2019
- Published by Springer Nature in Translational Psychiatry
- Vol. 9 (1) , 1-10
Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
Accumulating evidence points towards the antipsychotic potential of cannabidiol. However, the neurocognitive mechanisms underlying the antipsychotic effect of cannabidiol remain unclear. We investigated this in a double-blind, placebo-controlled, parallel-arm study. We investigated 33 antipsychotic-naïve subjects at clinical high risk for psychosis (CHR) randomised to 600 mg oral cannabidiol or placebo and compared them with 19 healthy controls. We used the monetary incentive delay task while participants underwent fMRI to study reward processing, known to be abnormal in psychosis. Reward and loss anticipation phases were combined to examine a motivational salience condition and compared with neutral condition. We observed abnormal activation in the left insula/parietal operculum in CHR participants given placebo compared to healthy controls associated with premature action initiation. Insular activation correlated with both positive psychotic symptoms and salience perception, as indexed by difference in reaction time between salient and neutral stimuli conditions. CBD attenuated the increased activation in the left insula/parietal operculum and was associated with overall slowing of reaction time, suggesting a possible mechanism for its putative antipsychotic effect by normalising motivational salience and moderating motor response.
- 22 August 2019
- Published by Springer Nature in Translational Psychiatry
- Vol. 9 (1) , 1-10
Open AccessCannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
Accumulating evidence points towards the antipsychotic potential of cannabidiol. However, the neurocognitive mechanisms underlying the antipsychotic effect of cannabidiol remain unclear. We investigated this in a double-blind, placebo-controlled, parallel-arm study. We investigated 33 antipsychotic-naïve subjects at clinical high risk for psychosis (CHR) randomised to 600 mg oral cannabidiol or placebo and compared them with 19 healthy controls. We used the monetary incentive delay task while participants underwent fMRI to study reward processing, known to be abnormal in psychosis. Reward and loss anticipation phases were combined to examine a motivational salience condition and compared with neutral condition. We observed abnormal activation in the left insula/parietal operculum in CHR participants given placebo compared to healthy controls associated with premature action initiation. Insular activation correlated with both positive psychotic symptoms and salience perception, as indexed by difference in reaction time between salient and neutral stimuli conditions. CBD attenuated the increased activation in the left insula/parietal operculum and was associated with overall slowing of reaction time, suggesting a possible mechanism for its putative antipsychotic effect by normalising motivational salience and moderating motor response.
- Open Access
- 20 June 2019
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 46 (1) , 110-120
What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors
Twenty percent of individuals at clinical high risk for psychosis (CHR-P) develop the disorder within 2 years. Extensive research has explored the factors that differentiate those who develop psychosis and those who do not, but the results are conflicting.The current systematic review and meta-analysis comprehensively addresses the consistency and magnitude of evidence for non-purely genetic risk and protective factors associated with the risk of developing psychosis in CHR-P individuals. Random effects meta-analyses, standardized mean difference (SMD) and odds ratio (OR) were used, in combination with an established stratification of evidence that assesses the association of each factor and the onset of psychotic disorders (from class I, convincing evidence to class IV weak evidence), while controlling for several types of biases.A total of 128 original controlled studies relating to 26 factors were retrieved. No factors showed class I-convincing evidence. Two further factors were associated with class II-highly suggestive evidence: attenuated positive psychotic symptoms (SMD = 0.348, 95% CI: 0.280, 0.415) and global functioning (SMD = −0.291, 95% CI: −0.370, −0.211). There was class III-suggestive evidence for negative psychotic symptoms (SMD = 0.393, 95% CI: 0.317, 0.469). There was either class IV-weak or no evidence for all other factors.Our findings suggest that despite the large number of putative risk factors investigated in the literature, only attenuated positive psychotic symptoms, global functioning, and negative psychotic symptoms show suggestive evidence or greater for association with transition to psychosis. The current findings may inform the refinement of clinical prediction models and precision medicine in this field.
- 20 June 2019
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 46 (1) , 110-120
Open AccessWhat Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors
Twenty percent of individuals at clinical high risk for psychosis (CHR-P) develop the disorder within 2 years. Extensive research has explored the factors that differentiate those who develop psychosis and those who do not, but the results are conflicting.The current systematic review and meta-analysis comprehensively addresses the consistency and magnitude of evidence for non-purely genetic risk and protective factors associated with the risk of developing psychosis in CHR-P individuals. Random effects meta-analyses, standardized mean difference (SMD) and odds ratio (OR) were used, in combination with an established stratification of evidence that assesses the association of each factor and the onset of psychotic disorders (from class I, convincing evidence to class IV weak evidence), while controlling for several types of biases.A total of 128 original controlled studies relating to 26 factors were retrieved. No factors showed class I-convincing evidence. Two further factors were associated with class II-highly suggestive evidence: attenuated positive psychotic symptoms (SMD = 0.348, 95% CI: 0.280, 0.415) and global functioning (SMD = −0.291, 95% CI: −0.370, −0.211). There was class III-suggestive evidence for negative psychotic symptoms (SMD = 0.393, 95% CI: 0.317, 0.469). There was either class IV-weak or no evidence for all other factors.Our findings suggest that despite the large number of putative risk factors investigated in the literature, only attenuated positive psychotic symptoms, global functioning, and negative psychotic symptoms show suggestive evidence or greater for association with transition to psychosis. The current findings may inform the refinement of clinical prediction models and precision medicine in this field.
- 1 June 2019
- Published by Elsevier in Schizophrenia Research
- Vol. 208, 209-216
Towards a framework for good outcome in people at clinical high risk for psychosis: A Delphi consensus study
- 1 June 2019
- Published by Elsevier in Schizophrenia Research
- Vol. 208, 209-216
Towards a framework for good outcome in people at clinical high risk for psychosis: A Delphi consensus study
- Open Access
- 1 April 2018
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 44 (suppl_1) , S374
S126. GOOD OUTCOME IN INDIVIDUALS AT ULTRA-HIGH RISK (UHR) OF DEVELOPING PSYCHOSIS: A DELPHI STUDY
- 1 April 2018
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 44 (suppl_1) , S374
Open AccessS126. GOOD OUTCOME IN INDIVIDUALS AT ULTRA-HIGH RISK (UHR) OF DEVELOPING PSYCHOSIS: A DELPHI STUDY
- Open Access
- 1 September 2017
- Published by Elsevier in Psychiatry Research
- Vol. 255, 36-41
Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis
- 1 September 2017
- Published by Elsevier in Psychiatry Research
- Vol. 255, 36-41
Open AccessEffect of continued cannabis use on medication adherence in the first two years following onset of psychosis
- Open Access
- 1 August 2017
- Published by Elsevier in The Lancet Psychiatry
- Vol. 4 (8) , 627-633
Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis
- 1 August 2017
- Published by Elsevier in The Lancet Psychiatry
- Vol. 4 (8) , 627-633
Open AccessPoor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis